The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer

Immune checkpoint inhibitors (ICIs) are newer therapies being applied to an increasing number of patients with cancer. Data suggest that up to 36% of cancer patients may be eligible for immunotherapy and, in late 2019, there were more than 3,362 clinical trials initiated to evaluate the effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lili, Reynolds, Kerry L., Lyon, Alexander R., Palaskas, Nicolas, Neilan, Tomas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Primers in Cardio-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034586/
https://www.ncbi.nlm.nih.gov/pubmed/33842895
http://dx.doi.org/10.1016/j.jaccao.2020.11.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034586/
https://www.ncbi.nlm.nih.gov/pubmed/33842895
http://dx.doi.org/10.1016/j.jaccao.2020.11.012

Ejemplares similares